No abstract

No abstract

No abstract

No abstract

No abstract

Background: Postoperative length of stay (LOS) of 1 day compared with that of 2 to 4 days after primary total knee arthroplasty (TKA) or total hip arthroplasty (THA) and 90-day readmissions. Methods: PearlDiver identified TKA (n = 648,758) and THA patients (n = 346,732) between 2005 and 2014. Groups consisted of control (LOS = 1 day) and study (LOS = 2 to 4 days) groups. Study and control groups were matched to age, sex, and Elixhauser Comorbidity Index. Logistic regression analysis and odds ratio analyzed 90-day readmission rates. P , 0.05 was statistically significant. Results: TKA patients' LOS of 2 days (odds ratio [OR], 2.89; 95% confidence interval [CI], 2.77 to 3.00), LOS of 3 days (OR, 2.80; 95% CI, 2.69 to 2.91), and LOS of 4 days (OR, 2.83; 95% CI, 2.72 to 2.95) had greater 90-day readmission compared with LOS of 1 day (P , 0.05). THA patients with an LOS of 2 days (OR, 2.93; 95% CI, 2.77 to 3.10), an LOS of 3 days (OR, 2.91; 95% CI, 2.75 to 3.07), or an LOS of 4 days (OR, 2.91; 95% CI, 2.73 to 3.05) had greater 90-day readmission compared with an LOS of 1 day (P , 0.05). Conclusion: LOS .1 day has greater odds of 90-day readmission after an index procedure. Efficient progression to early discharge regarding patient-specific risk factors plays a large role in preventing readmission. Recent efforts within total joint arthroplasty (TJA) have focused on reducing the episode of care costs without sacrificing quality of care and patient outcomes. 1-3 Minimizing postoperative readmission rates decreases overall costs and healthcare burden, as well as postprocedural morbidity, and has become a major surrogate for assessing surgical outcomes. [1][2][3] However, in efforts to identify those specific risk factors which may predispose to unplanned readmission, studies present conflicting evidence, particularly regarding the significance of in-hospital length of stay (LOS) after surgery.Mean hospital LOS decreased from 9.1 days to 3.7 days, whereas 30-day all-cause readmission rates increased from 5.9% to 8.5%; however, the

No abstract

Avascular necrosis (AVN) is a degenerative bone condition characterized by cellular death and bone collapse from compromised subchondral blood circulation. AVN begins with vascular interruption, hypertension, intravascular occlusion, or extravascular compression which reduces bone circulation. Although corticosteroids are frequently used to treat acute COVID-19 infections, patients are prone to its side effects, particularly AVN. Furthermore, COVID-19 produces coagulopathies, specifically hypercoagulability, that may contribute to venous thrombosis, which may serve as the impetus of AVN. While the literature discussing COVID-19, AVN, and corticosteroid use is not conclusive, patients being treated with corticosteroids for COVID-19 are at an increased risk for AVN possibly due to the combination of COVID-19 infection and corticosteroid use, or the use of high-dose steroids alone. The purpose of this case series is to elucidate AVN as a long-term sequalae of COVID-19, describe our management of COVID-19 and steroidinduced AVN, and discuss the current literature regarding AVN and COVID-19. Three patients hospitalized for COVID-19 infections were treated with corticosteroids and subsequently developed AVN. All patients, but one, had multiple sites of infarction and were treated with core decompression in the hip where there was no collapse of the subchondral bone. One of these patients had multiple infarcts in bilateral femoral heads, femoral shafts, and knees. This patient had a history of end-stage renal disease, and, therefore, total knee replacement was postponed until medical clearance. Core decompression was performed on the femoral head that showed no collapse to delay osteoarthritis of the hip. Multiple articles in the current literature support the idea that the combination of COVID-19 and corticosteroid use increases the risk of AVN and reduces the onset of COVID-19-related respiratory symptoms. The patient cases discussed in this case series suggest a possible association between COVID-19, corticosteroid use, and AVN.